Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors

被引:27
作者
Zeng, Huahui [1 ]
Zhang, Huabei [1 ]
机构
[1] Beijing Normal Univ, Coll Chem, Minist Educ, Key Lab Radiopharmaceut, Beijing 100875, Peoples R China
关键词
VEGFR-2; 1,4-dihydroindeno[1,2-c]pyrazoles; 3D-QSAR; CoMFA; CoMSIA; Molecular docking; ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; PARTIAL LEAST-SQUARES; ANTITUMOR EFFICACY; SIMILARITY INDEXES; FIELD ANALYSIS; ANGIOGENESIS; DISCOVERY; BINDING; CANCER;
D O I
10.1016/j.jmgm.2010.04.004
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The vascular endothelial growth factor (VEGF) and its receptor tyrosine kinases VEGFR-2 are attractive targets for the development of novel anticancer agents. To understand the structure-activity correlation of 1,4-dihydroindeno[1,2-c]pyrazole-based VEGFR-2 inhibitors, we have carried out a combined molecular docking and three-dimensional quantitative structure-activity relationship (3D-QSAR) modeling study. The study has resulted in two types of satisfactory substructure-based 3D-QSAR models, including the CoMFA model (r(2), 0.931; q(2), 0.600) and CoMSIA model (r(2), 0.928; q(2), 0.569), for predicting the biological activity of new compounds. The detailed microscopic structures of VEGFR-2 binding with inhibitors have been studied by molecular docking. We have also developed docking based 3D-QSAR models (CoMFA with r(2), 0.958; q(2), 0.563; CoMSIA with r(2), 0.965; q(2), 0.567). The contour maps obtained from the 3D-QSAR models in combination with the docked binding structures help to better interpret the structure-activity relationship. All of the structural insights obtained from both the 3D-QSAR contour maps and molecular docking are consistent with the available experimental activity data. The satisfactory results strongly suggest that the developed 3D-QSAR models and the obtained VEGFR-2 inhibitor binding structures are reasonable for the prediction of the activity of new inhibitors and in future drug design. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:54 / 71
页数:18
相关论文
共 60 条
[1]   Kinase inhibition with BAY 43-9006 n renal cell carcinoma [J].
Ahmad, T ;
Eisen, T .
CLINICAL CANCER RESEARCH, 2004, 10 (18) :6388S-6392S
[2]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[3]   Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors [J].
Akritopoulou-Zanze, Irim ;
Albert, Daniel H. ;
Bousquet, Peter F. ;
Cunha, George A. ;
Harris, Christopher M. ;
Moskey, Maria ;
Dinges, Jurgen ;
Stewart, Kent D. ;
Sowin, Thomas J. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (11) :3136-3140
[4]   A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis [J].
Baka, Sofia ;
Clamp, Andrew R. ;
Jayson, Gordon C. .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2006, 10 (06) :867-876
[5]  
Beebe JS, 2003, CANCER RES, V63, P7301
[6]   Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor [J].
Bhide, RS ;
Cai, ZW ;
Zhang, YZ ;
Qian, LG ;
Wei, D ;
Barbosa, S ;
Lombardo, LJ ;
Borzilleri, RM ;
Zheng, XP ;
Wu, LI ;
Barrish, JC ;
Kim, SH ;
Leavitt, K ;
Mathur, A ;
Leith, L ;
Chao, S ;
Wautlet, B ;
Mortillo, S ;
Jeyaseelan, R ;
Kukral, D ;
Hunt, JT ;
Kamath, A ;
Fura, A ;
Vyas, V ;
Marathe, P ;
D'Arienzo, C ;
Derbin, G ;
Fargnoli, J .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (07) :2143-2146
[7]   Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa [J].
Böhm, M ;
Stürzebecher, J ;
Klebe, G .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (03) :458-477
[8]   Discovery and evaluation of N-cyclopropyl-2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5-ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2 [J].
Borzilleri, Robert M. ;
Bhide, Rajeev S. ;
Barrish, Joel C. ;
D'Arienzo, Celia J. ;
Derbin, George M. ;
Fargnoli, Joseph ;
Hunt, John T. ;
Jeyaseelan, Robert, Sr. ;
Kamath, Amrita ;
Kukral, Daniel W. ;
Marathe, Punit ;
Mortillo, Steve ;
Qian, Ligang ;
Tokarski, John S. ;
Wautlet, Barri S. ;
Zheng, Xiaoping ;
Lombardo, Louis J. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (13) :3766-3769
[9]   SAMPLE-DISTANCE PARTIAL LEAST-SQUARES - PLS OPTIMIZED FOR MANY VARIABLES, WITH APPLICATION TO COMFA [J].
BUSH, BL ;
NACHBAR, RB .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1993, 7 (05) :587-619
[10]   Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl) phenylamino] pyrrolo [2,1-f][1,2,4] triazine-based VEGFR-2 kinase inhibitors [J].
Cai, Zhen-wei ;
Wei, Donna ;
Borzilleri, Robert M. ;
Qian, Ligang ;
Kamath, Amrita ;
Mortillo, Steven ;
Wautlet, Barri ;
Henley, Benjamin J. ;
Jeyaseelan, Robert, Sr. ;
Tokarski, John ;
Hunt, John T. ;
Bhide, Rajeev S. ;
Fargnoli, Joseph ;
Lombardo, Louis J. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (04) :1354-1358